Flamel Technologies Announces License Agreement With Wyeth

French biopharmaceutical company Flamel Technologies announced that it has entered into an agreement with Wyeth Pharmaceuticals for the development and licensing of a marketed protein to be delivered using Flamel’s Medusa technology.

Medusa is designed to deliver controlled-release formulations of therapeutic proteins and peptides and other molecules without reduction in bioactivity, Flamel said.

Stephen Willard, Flamel’s CEO, said that the agreement with Wyeth was the fourth Medusa partnership the company has entered into this year. He added that the agreement concerns the Flamel’s uniform polymer that is applicable to a variety of peptides and proteins.

Flamel said it will receive an upfront payment and potential development fees, milestones and royalty payments. The companies did not disclose the terms of the agreement.